Development of a surface enhanced Raman scattering (SERS) sensor for point of care therapeutic drug monitoring in canine epilepsy

BBSRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

September 29, 2028
Response Due
Active
Status

Opportunity Overview

Epilepsy is the most prevalent neurological condition in canines, affecting 1.5-2% of dogs. In most cases, canine epilepsy is idiopathic and the condition is still poorly understood. Since epilepsy is incurable, treatment is intended to control the symptoms by reducing frequency and intensity of seizures, while minimizing side effects. Therapeutic drug monitoring is therefore required to ensure the correct quantity of drug is administered and to confirm the efficacy of the drugs with minimal adverse effects. Phenobarbitone is the most commonly prescribed medication for canine epilepsy. Generally, the drug would be monitored by taking blood tests at the beginning of treatment and on occurrence of seizures; however, a quicker and less invasive test could provide a significant step in the understanding of idiopathic epilepsy and in monitoring drug treatment. An ideal route to achieving this would be the development of a point-of-care (POC) sensor that could detect the drug in saliva, allowing regular non-invasive monitoring that could potentially be correlated with circulating levels of the drug in routine blood tests. The POC test would allow closer monitoring of drug levels and the correlation with onset of seizures, while minimizing patient distress.
Surface enhanced Raman scattering (SERS) is an ultrasensitive and highly specific technique that can be used for the label-free quantification of analytes. Since SERS gives molecularly specific vibrational information, analytes can be specifically identified and the unique SERS spectra obtained from individual molecules enables the detection and quantification of multiple targets simultaneously. These attributes make SERS an attractive technique for POC analysis and its use has been demonstrated in various applications from drug analysis to medical diagnosis and in food safety.
The basis of SERS is that an enhancing substrate, usually in the form of metallic nanomaterials, will significantly increase the intrinsic...

This is one of 44 active United Kingdom Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyBBSRC
CountryUnited Kingdom
CategoryPharmaceuticals
PublishedSeptember 30, 2024
Procurement stageActive solicitation
Response dueSeptember 29, 2028
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Pharmaceutical Wholesale Services
Community Drug and Alcohol Services
Provision of Drug, Alcohol & DNA Testing Services Framework
Personalised Adaptive Medicine
Repurposing Epigenetic Therapy for Hypertrophic Cardiomyopathy to facilitate the innovation and growth of a N.Ireland Cardiac Drug Development Company
Smallpox Vaccine (2026)
Integrated Drug and Alcohol Treatment and Recovery Service
Meningococcal ACWY vaccine (2027)

See every United Kingdom Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Pharmaceuticals intelligence report in your inbox

A personalized report on United Kingdom Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.